Mesenchymal stem cell therapy for alleviating ocular surface inflammation in allergic conjunctivitis
Allergic eye diseases have become a major concern worldwide, especially in the paediatric population. Vernal keratoconjunctivitis, a seasonal, chronic, bilateral inflammation of the ocular surface, represents one of the most common forms of ocular allergy in subtropical climates which may lead to co...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Bhure, Tejal Sunil [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2022transfer abstract |
|---|
| Schlagwörter: |
|---|
| Übergeordnetes Werk: |
Enthalten in: Hierarchical porous NiCo2S4-rGO composites for high-performance supercapacitors - Fan, Ya-Meng ELSEVIER, 2017transfer abstract, Burlington, Mass |
|---|---|
| Übergeordnetes Werk: |
volume:162 ; year:2022 ; pages:0 |
| Links: |
|---|
| DOI / URN: |
10.1016/j.mehy.2022.110813 |
|---|
| Katalog-ID: |
ELV057401594 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | ELV057401594 | ||
| 003 | DE-627 | ||
| 005 | 20230626045036.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 220808s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.mehy.2022.110813 |2 doi | |
| 028 | 5 | 2 | |a /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001735.pica |
| 035 | |a (DE-627)ELV057401594 | ||
| 035 | |a (ELSEVIER)S0306-9877(22)00053-6 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 540 |q VZ |
| 082 | 0 | 4 | |a 610 |q VZ |
| 084 | |a 44.00 |2 bkl | ||
| 100 | 1 | |a Bhure, Tejal Sunil |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Mesenchymal stem cell therapy for alleviating ocular surface inflammation in allergic conjunctivitis |
| 264 | 1 | |c 2022transfer abstract | |
| 336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
| 337 | |a nicht spezifiziert |b z |2 rdamedia | ||
| 338 | |a nicht spezifiziert |b zu |2 rdacarrier | ||
| 520 | |a Allergic eye diseases have become a major concern worldwide, especially in the paediatric population. Vernal keratoconjunctivitis, a seasonal, chronic, bilateral inflammation of the ocular surface, represents one of the most common forms of ocular allergy in subtropical climates which may lead to corneal scarring and blindness if not properly treated. Late diagnosis of the disease and potential side effects of the currently used topical steroids, antihistamines, and mast cell stabilizers necessitates the development of early diagnostic tools and alternate immunosuppressive therapies. Mesenchymal stem cells have shown promising therapeutic potentials due to their tissue repair, anti-allergic, and immunomodulatory properties. However, their role in allergic conjunctivitis/vernal keratoconjunctivitis is poorly explored. Here, it is hypothesized that mesenchymal stem cells or their secreted products alleviate inflammation and promote repair of the damaged ocular surface in allergic conjunctivitis patients. It is presumed that they do so through multiple anti-allergic mechanisms and maintain long-term immunosuppression with significantly reduced or negligible side effects. These cells or their secreted products (extracellular vesicles, growth factors, conditioned medium, inflammatory mediators, and other biomolecules) can be used as topical immunosuppressive medications for effectively treating ocular surface inflammation in allergic conjunctivitis. | ||
| 520 | |a Allergic eye diseases have become a major concern worldwide, especially in the paediatric population. Vernal keratoconjunctivitis, a seasonal, chronic, bilateral inflammation of the ocular surface, represents one of the most common forms of ocular allergy in subtropical climates which may lead to corneal scarring and blindness if not properly treated. Late diagnosis of the disease and potential side effects of the currently used topical steroids, antihistamines, and mast cell stabilizers necessitates the development of early diagnostic tools and alternate immunosuppressive therapies. Mesenchymal stem cells have shown promising therapeutic potentials due to their tissue repair, anti-allergic, and immunomodulatory properties. However, their role in allergic conjunctivitis/vernal keratoconjunctivitis is poorly explored. Here, it is hypothesized that mesenchymal stem cells or their secreted products alleviate inflammation and promote repair of the damaged ocular surface in allergic conjunctivitis patients. It is presumed that they do so through multiple anti-allergic mechanisms and maintain long-term immunosuppression with significantly reduced or negligible side effects. These cells or their secreted products (extracellular vesicles, growth factors, conditioned medium, inflammatory mediators, and other biomolecules) can be used as topical immunosuppressive medications for effectively treating ocular surface inflammation in allergic conjunctivitis. | ||
| 650 | 7 | |a Eye |2 Elsevier | |
| 650 | 7 | |a Allergy |2 Elsevier | |
| 650 | 7 | |a Allergic conjunctivitis |2 Elsevier | |
| 650 | 7 | |a Immunomodulation |2 Elsevier | |
| 650 | 7 | |a Secretome |2 Elsevier | |
| 650 | 7 | |a Mesenchymal stem cells |2 Elsevier | |
| 700 | 1 | |a Das, Prabhudatta |4 oth | |
| 700 | 1 | |a Jukanti, Avinash |4 oth | |
| 700 | 1 | |a Mishra, Dilip Kumar |4 oth | |
| 700 | 1 | |a Sahu, Srikant Kumar |4 oth | |
| 700 | 1 | |a Basu, Sayan |4 oth | |
| 700 | 1 | |a Shukla, Sachin |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |n Harcourt |a Fan, Ya-Meng ELSEVIER |t Hierarchical porous NiCo2S4-rGO composites for high-performance supercapacitors |d 2017transfer abstract |g Burlington, Mass |w (DE-627)ELV015462293 |
| 773 | 1 | 8 | |g volume:162 |g year:2022 |g pages:0 |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.mehy.2022.110813 |3 Volltext |
| 912 | |a GBV_USEFLAG_U | ||
| 912 | |a GBV_ELV | ||
| 912 | |a SYSFLAG_U | ||
| 912 | |a SSG-OLC-PHA | ||
| 936 | b | k | |a 44.00 |j Medizin: Allgemeines |q VZ |
| 951 | |a AR | ||
| 952 | |d 162 |j 2022 |h 0 | ||
| author_variant |
t s b ts tsb |
|---|---|
| matchkey_str |
bhuretejalsunildasprabhudattajukantiavin:2022----:eecyaseclteayoalvaigclrufcifamtoi |
| hierarchy_sort_str |
2022transfer abstract |
| bklnumber |
44.00 |
| publishDate |
2022 |
| allfields |
10.1016/j.mehy.2022.110813 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001735.pica (DE-627)ELV057401594 (ELSEVIER)S0306-9877(22)00053-6 DE-627 ger DE-627 rakwb eng 540 VZ 610 VZ 44.00 bkl Bhure, Tejal Sunil verfasserin aut Mesenchymal stem cell therapy for alleviating ocular surface inflammation in allergic conjunctivitis 2022transfer abstract nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Allergic eye diseases have become a major concern worldwide, especially in the paediatric population. Vernal keratoconjunctivitis, a seasonal, chronic, bilateral inflammation of the ocular surface, represents one of the most common forms of ocular allergy in subtropical climates which may lead to corneal scarring and blindness if not properly treated. Late diagnosis of the disease and potential side effects of the currently used topical steroids, antihistamines, and mast cell stabilizers necessitates the development of early diagnostic tools and alternate immunosuppressive therapies. Mesenchymal stem cells have shown promising therapeutic potentials due to their tissue repair, anti-allergic, and immunomodulatory properties. However, their role in allergic conjunctivitis/vernal keratoconjunctivitis is poorly explored. Here, it is hypothesized that mesenchymal stem cells or their secreted products alleviate inflammation and promote repair of the damaged ocular surface in allergic conjunctivitis patients. It is presumed that they do so through multiple anti-allergic mechanisms and maintain long-term immunosuppression with significantly reduced or negligible side effects. These cells or their secreted products (extracellular vesicles, growth factors, conditioned medium, inflammatory mediators, and other biomolecules) can be used as topical immunosuppressive medications for effectively treating ocular surface inflammation in allergic conjunctivitis. Allergic eye diseases have become a major concern worldwide, especially in the paediatric population. Vernal keratoconjunctivitis, a seasonal, chronic, bilateral inflammation of the ocular surface, represents one of the most common forms of ocular allergy in subtropical climates which may lead to corneal scarring and blindness if not properly treated. Late diagnosis of the disease and potential side effects of the currently used topical steroids, antihistamines, and mast cell stabilizers necessitates the development of early diagnostic tools and alternate immunosuppressive therapies. Mesenchymal stem cells have shown promising therapeutic potentials due to their tissue repair, anti-allergic, and immunomodulatory properties. However, their role in allergic conjunctivitis/vernal keratoconjunctivitis is poorly explored. Here, it is hypothesized that mesenchymal stem cells or their secreted products alleviate inflammation and promote repair of the damaged ocular surface in allergic conjunctivitis patients. It is presumed that they do so through multiple anti-allergic mechanisms and maintain long-term immunosuppression with significantly reduced or negligible side effects. These cells or their secreted products (extracellular vesicles, growth factors, conditioned medium, inflammatory mediators, and other biomolecules) can be used as topical immunosuppressive medications for effectively treating ocular surface inflammation in allergic conjunctivitis. Eye Elsevier Allergy Elsevier Allergic conjunctivitis Elsevier Immunomodulation Elsevier Secretome Elsevier Mesenchymal stem cells Elsevier Das, Prabhudatta oth Jukanti, Avinash oth Mishra, Dilip Kumar oth Sahu, Srikant Kumar oth Basu, Sayan oth Shukla, Sachin oth Enthalten in Harcourt Fan, Ya-Meng ELSEVIER Hierarchical porous NiCo2S4-rGO composites for high-performance supercapacitors 2017transfer abstract Burlington, Mass (DE-627)ELV015462293 volume:162 year:2022 pages:0 https://doi.org/10.1016/j.mehy.2022.110813 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 44.00 Medizin: Allgemeines VZ AR 162 2022 0 |
| spelling |
10.1016/j.mehy.2022.110813 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001735.pica (DE-627)ELV057401594 (ELSEVIER)S0306-9877(22)00053-6 DE-627 ger DE-627 rakwb eng 540 VZ 610 VZ 44.00 bkl Bhure, Tejal Sunil verfasserin aut Mesenchymal stem cell therapy for alleviating ocular surface inflammation in allergic conjunctivitis 2022transfer abstract nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Allergic eye diseases have become a major concern worldwide, especially in the paediatric population. Vernal keratoconjunctivitis, a seasonal, chronic, bilateral inflammation of the ocular surface, represents one of the most common forms of ocular allergy in subtropical climates which may lead to corneal scarring and blindness if not properly treated. Late diagnosis of the disease and potential side effects of the currently used topical steroids, antihistamines, and mast cell stabilizers necessitates the development of early diagnostic tools and alternate immunosuppressive therapies. Mesenchymal stem cells have shown promising therapeutic potentials due to their tissue repair, anti-allergic, and immunomodulatory properties. However, their role in allergic conjunctivitis/vernal keratoconjunctivitis is poorly explored. Here, it is hypothesized that mesenchymal stem cells or their secreted products alleviate inflammation and promote repair of the damaged ocular surface in allergic conjunctivitis patients. It is presumed that they do so through multiple anti-allergic mechanisms and maintain long-term immunosuppression with significantly reduced or negligible side effects. These cells or their secreted products (extracellular vesicles, growth factors, conditioned medium, inflammatory mediators, and other biomolecules) can be used as topical immunosuppressive medications for effectively treating ocular surface inflammation in allergic conjunctivitis. Allergic eye diseases have become a major concern worldwide, especially in the paediatric population. Vernal keratoconjunctivitis, a seasonal, chronic, bilateral inflammation of the ocular surface, represents one of the most common forms of ocular allergy in subtropical climates which may lead to corneal scarring and blindness if not properly treated. Late diagnosis of the disease and potential side effects of the currently used topical steroids, antihistamines, and mast cell stabilizers necessitates the development of early diagnostic tools and alternate immunosuppressive therapies. Mesenchymal stem cells have shown promising therapeutic potentials due to their tissue repair, anti-allergic, and immunomodulatory properties. However, their role in allergic conjunctivitis/vernal keratoconjunctivitis is poorly explored. Here, it is hypothesized that mesenchymal stem cells or their secreted products alleviate inflammation and promote repair of the damaged ocular surface in allergic conjunctivitis patients. It is presumed that they do so through multiple anti-allergic mechanisms and maintain long-term immunosuppression with significantly reduced or negligible side effects. These cells or their secreted products (extracellular vesicles, growth factors, conditioned medium, inflammatory mediators, and other biomolecules) can be used as topical immunosuppressive medications for effectively treating ocular surface inflammation in allergic conjunctivitis. Eye Elsevier Allergy Elsevier Allergic conjunctivitis Elsevier Immunomodulation Elsevier Secretome Elsevier Mesenchymal stem cells Elsevier Das, Prabhudatta oth Jukanti, Avinash oth Mishra, Dilip Kumar oth Sahu, Srikant Kumar oth Basu, Sayan oth Shukla, Sachin oth Enthalten in Harcourt Fan, Ya-Meng ELSEVIER Hierarchical porous NiCo2S4-rGO composites for high-performance supercapacitors 2017transfer abstract Burlington, Mass (DE-627)ELV015462293 volume:162 year:2022 pages:0 https://doi.org/10.1016/j.mehy.2022.110813 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 44.00 Medizin: Allgemeines VZ AR 162 2022 0 |
| allfields_unstemmed |
10.1016/j.mehy.2022.110813 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001735.pica (DE-627)ELV057401594 (ELSEVIER)S0306-9877(22)00053-6 DE-627 ger DE-627 rakwb eng 540 VZ 610 VZ 44.00 bkl Bhure, Tejal Sunil verfasserin aut Mesenchymal stem cell therapy for alleviating ocular surface inflammation in allergic conjunctivitis 2022transfer abstract nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Allergic eye diseases have become a major concern worldwide, especially in the paediatric population. Vernal keratoconjunctivitis, a seasonal, chronic, bilateral inflammation of the ocular surface, represents one of the most common forms of ocular allergy in subtropical climates which may lead to corneal scarring and blindness if not properly treated. Late diagnosis of the disease and potential side effects of the currently used topical steroids, antihistamines, and mast cell stabilizers necessitates the development of early diagnostic tools and alternate immunosuppressive therapies. Mesenchymal stem cells have shown promising therapeutic potentials due to their tissue repair, anti-allergic, and immunomodulatory properties. However, their role in allergic conjunctivitis/vernal keratoconjunctivitis is poorly explored. Here, it is hypothesized that mesenchymal stem cells or their secreted products alleviate inflammation and promote repair of the damaged ocular surface in allergic conjunctivitis patients. It is presumed that they do so through multiple anti-allergic mechanisms and maintain long-term immunosuppression with significantly reduced or negligible side effects. These cells or their secreted products (extracellular vesicles, growth factors, conditioned medium, inflammatory mediators, and other biomolecules) can be used as topical immunosuppressive medications for effectively treating ocular surface inflammation in allergic conjunctivitis. Allergic eye diseases have become a major concern worldwide, especially in the paediatric population. Vernal keratoconjunctivitis, a seasonal, chronic, bilateral inflammation of the ocular surface, represents one of the most common forms of ocular allergy in subtropical climates which may lead to corneal scarring and blindness if not properly treated. Late diagnosis of the disease and potential side effects of the currently used topical steroids, antihistamines, and mast cell stabilizers necessitates the development of early diagnostic tools and alternate immunosuppressive therapies. Mesenchymal stem cells have shown promising therapeutic potentials due to their tissue repair, anti-allergic, and immunomodulatory properties. However, their role in allergic conjunctivitis/vernal keratoconjunctivitis is poorly explored. Here, it is hypothesized that mesenchymal stem cells or their secreted products alleviate inflammation and promote repair of the damaged ocular surface in allergic conjunctivitis patients. It is presumed that they do so through multiple anti-allergic mechanisms and maintain long-term immunosuppression with significantly reduced or negligible side effects. These cells or their secreted products (extracellular vesicles, growth factors, conditioned medium, inflammatory mediators, and other biomolecules) can be used as topical immunosuppressive medications for effectively treating ocular surface inflammation in allergic conjunctivitis. Eye Elsevier Allergy Elsevier Allergic conjunctivitis Elsevier Immunomodulation Elsevier Secretome Elsevier Mesenchymal stem cells Elsevier Das, Prabhudatta oth Jukanti, Avinash oth Mishra, Dilip Kumar oth Sahu, Srikant Kumar oth Basu, Sayan oth Shukla, Sachin oth Enthalten in Harcourt Fan, Ya-Meng ELSEVIER Hierarchical porous NiCo2S4-rGO composites for high-performance supercapacitors 2017transfer abstract Burlington, Mass (DE-627)ELV015462293 volume:162 year:2022 pages:0 https://doi.org/10.1016/j.mehy.2022.110813 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 44.00 Medizin: Allgemeines VZ AR 162 2022 0 |
| allfieldsGer |
10.1016/j.mehy.2022.110813 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001735.pica (DE-627)ELV057401594 (ELSEVIER)S0306-9877(22)00053-6 DE-627 ger DE-627 rakwb eng 540 VZ 610 VZ 44.00 bkl Bhure, Tejal Sunil verfasserin aut Mesenchymal stem cell therapy for alleviating ocular surface inflammation in allergic conjunctivitis 2022transfer abstract nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Allergic eye diseases have become a major concern worldwide, especially in the paediatric population. Vernal keratoconjunctivitis, a seasonal, chronic, bilateral inflammation of the ocular surface, represents one of the most common forms of ocular allergy in subtropical climates which may lead to corneal scarring and blindness if not properly treated. Late diagnosis of the disease and potential side effects of the currently used topical steroids, antihistamines, and mast cell stabilizers necessitates the development of early diagnostic tools and alternate immunosuppressive therapies. Mesenchymal stem cells have shown promising therapeutic potentials due to their tissue repair, anti-allergic, and immunomodulatory properties. However, their role in allergic conjunctivitis/vernal keratoconjunctivitis is poorly explored. Here, it is hypothesized that mesenchymal stem cells or their secreted products alleviate inflammation and promote repair of the damaged ocular surface in allergic conjunctivitis patients. It is presumed that they do so through multiple anti-allergic mechanisms and maintain long-term immunosuppression with significantly reduced or negligible side effects. These cells or their secreted products (extracellular vesicles, growth factors, conditioned medium, inflammatory mediators, and other biomolecules) can be used as topical immunosuppressive medications for effectively treating ocular surface inflammation in allergic conjunctivitis. Allergic eye diseases have become a major concern worldwide, especially in the paediatric population. Vernal keratoconjunctivitis, a seasonal, chronic, bilateral inflammation of the ocular surface, represents one of the most common forms of ocular allergy in subtropical climates which may lead to corneal scarring and blindness if not properly treated. Late diagnosis of the disease and potential side effects of the currently used topical steroids, antihistamines, and mast cell stabilizers necessitates the development of early diagnostic tools and alternate immunosuppressive therapies. Mesenchymal stem cells have shown promising therapeutic potentials due to their tissue repair, anti-allergic, and immunomodulatory properties. However, their role in allergic conjunctivitis/vernal keratoconjunctivitis is poorly explored. Here, it is hypothesized that mesenchymal stem cells or their secreted products alleviate inflammation and promote repair of the damaged ocular surface in allergic conjunctivitis patients. It is presumed that they do so through multiple anti-allergic mechanisms and maintain long-term immunosuppression with significantly reduced or negligible side effects. These cells or their secreted products (extracellular vesicles, growth factors, conditioned medium, inflammatory mediators, and other biomolecules) can be used as topical immunosuppressive medications for effectively treating ocular surface inflammation in allergic conjunctivitis. Eye Elsevier Allergy Elsevier Allergic conjunctivitis Elsevier Immunomodulation Elsevier Secretome Elsevier Mesenchymal stem cells Elsevier Das, Prabhudatta oth Jukanti, Avinash oth Mishra, Dilip Kumar oth Sahu, Srikant Kumar oth Basu, Sayan oth Shukla, Sachin oth Enthalten in Harcourt Fan, Ya-Meng ELSEVIER Hierarchical porous NiCo2S4-rGO composites for high-performance supercapacitors 2017transfer abstract Burlington, Mass (DE-627)ELV015462293 volume:162 year:2022 pages:0 https://doi.org/10.1016/j.mehy.2022.110813 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 44.00 Medizin: Allgemeines VZ AR 162 2022 0 |
| allfieldsSound |
10.1016/j.mehy.2022.110813 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001735.pica (DE-627)ELV057401594 (ELSEVIER)S0306-9877(22)00053-6 DE-627 ger DE-627 rakwb eng 540 VZ 610 VZ 44.00 bkl Bhure, Tejal Sunil verfasserin aut Mesenchymal stem cell therapy for alleviating ocular surface inflammation in allergic conjunctivitis 2022transfer abstract nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Allergic eye diseases have become a major concern worldwide, especially in the paediatric population. Vernal keratoconjunctivitis, a seasonal, chronic, bilateral inflammation of the ocular surface, represents one of the most common forms of ocular allergy in subtropical climates which may lead to corneal scarring and blindness if not properly treated. Late diagnosis of the disease and potential side effects of the currently used topical steroids, antihistamines, and mast cell stabilizers necessitates the development of early diagnostic tools and alternate immunosuppressive therapies. Mesenchymal stem cells have shown promising therapeutic potentials due to their tissue repair, anti-allergic, and immunomodulatory properties. However, their role in allergic conjunctivitis/vernal keratoconjunctivitis is poorly explored. Here, it is hypothesized that mesenchymal stem cells or their secreted products alleviate inflammation and promote repair of the damaged ocular surface in allergic conjunctivitis patients. It is presumed that they do so through multiple anti-allergic mechanisms and maintain long-term immunosuppression with significantly reduced or negligible side effects. These cells or their secreted products (extracellular vesicles, growth factors, conditioned medium, inflammatory mediators, and other biomolecules) can be used as topical immunosuppressive medications for effectively treating ocular surface inflammation in allergic conjunctivitis. Allergic eye diseases have become a major concern worldwide, especially in the paediatric population. Vernal keratoconjunctivitis, a seasonal, chronic, bilateral inflammation of the ocular surface, represents one of the most common forms of ocular allergy in subtropical climates which may lead to corneal scarring and blindness if not properly treated. Late diagnosis of the disease and potential side effects of the currently used topical steroids, antihistamines, and mast cell stabilizers necessitates the development of early diagnostic tools and alternate immunosuppressive therapies. Mesenchymal stem cells have shown promising therapeutic potentials due to their tissue repair, anti-allergic, and immunomodulatory properties. However, their role in allergic conjunctivitis/vernal keratoconjunctivitis is poorly explored. Here, it is hypothesized that mesenchymal stem cells or their secreted products alleviate inflammation and promote repair of the damaged ocular surface in allergic conjunctivitis patients. It is presumed that they do so through multiple anti-allergic mechanisms and maintain long-term immunosuppression with significantly reduced or negligible side effects. These cells or their secreted products (extracellular vesicles, growth factors, conditioned medium, inflammatory mediators, and other biomolecules) can be used as topical immunosuppressive medications for effectively treating ocular surface inflammation in allergic conjunctivitis. Eye Elsevier Allergy Elsevier Allergic conjunctivitis Elsevier Immunomodulation Elsevier Secretome Elsevier Mesenchymal stem cells Elsevier Das, Prabhudatta oth Jukanti, Avinash oth Mishra, Dilip Kumar oth Sahu, Srikant Kumar oth Basu, Sayan oth Shukla, Sachin oth Enthalten in Harcourt Fan, Ya-Meng ELSEVIER Hierarchical porous NiCo2S4-rGO composites for high-performance supercapacitors 2017transfer abstract Burlington, Mass (DE-627)ELV015462293 volume:162 year:2022 pages:0 https://doi.org/10.1016/j.mehy.2022.110813 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 44.00 Medizin: Allgemeines VZ AR 162 2022 0 |
| language |
English |
| source |
Enthalten in Hierarchical porous NiCo2S4-rGO composites for high-performance supercapacitors Burlington, Mass volume:162 year:2022 pages:0 |
| sourceStr |
Enthalten in Hierarchical porous NiCo2S4-rGO composites for high-performance supercapacitors Burlington, Mass volume:162 year:2022 pages:0 |
| format_phy_str_mv |
Article |
| bklname |
Medizin: Allgemeines |
| institution |
findex.gbv.de |
| topic_facet |
Eye Allergy Allergic conjunctivitis Immunomodulation Secretome Mesenchymal stem cells |
| dewey-raw |
540 |
| isfreeaccess_bool |
false |
| container_title |
Hierarchical porous NiCo2S4-rGO composites for high-performance supercapacitors |
| authorswithroles_txt_mv |
Bhure, Tejal Sunil @@aut@@ Das, Prabhudatta @@oth@@ Jukanti, Avinash @@oth@@ Mishra, Dilip Kumar @@oth@@ Sahu, Srikant Kumar @@oth@@ Basu, Sayan @@oth@@ Shukla, Sachin @@oth@@ |
| publishDateDaySort_date |
2022-01-01T00:00:00Z |
| hierarchy_top_id |
ELV015462293 |
| dewey-sort |
3540 |
| id |
ELV057401594 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV057401594</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230626045036.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">220808s2022 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.mehy.2022.110813</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">/cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001735.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV057401594</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S0306-9877(22)00053-6</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">540</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">44.00</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Bhure, Tejal Sunil</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Mesenchymal stem cell therapy for alleviating ocular surface inflammation in allergic conjunctivitis</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2022transfer abstract</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Allergic eye diseases have become a major concern worldwide, especially in the paediatric population. Vernal keratoconjunctivitis, a seasonal, chronic, bilateral inflammation of the ocular surface, represents one of the most common forms of ocular allergy in subtropical climates which may lead to corneal scarring and blindness if not properly treated. Late diagnosis of the disease and potential side effects of the currently used topical steroids, antihistamines, and mast cell stabilizers necessitates the development of early diagnostic tools and alternate immunosuppressive therapies. Mesenchymal stem cells have shown promising therapeutic potentials due to their tissue repair, anti-allergic, and immunomodulatory properties. However, their role in allergic conjunctivitis/vernal keratoconjunctivitis is poorly explored. Here, it is hypothesized that mesenchymal stem cells or their secreted products alleviate inflammation and promote repair of the damaged ocular surface in allergic conjunctivitis patients. It is presumed that they do so through multiple anti-allergic mechanisms and maintain long-term immunosuppression with significantly reduced or negligible side effects. These cells or their secreted products (extracellular vesicles, growth factors, conditioned medium, inflammatory mediators, and other biomolecules) can be used as topical immunosuppressive medications for effectively treating ocular surface inflammation in allergic conjunctivitis.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Allergic eye diseases have become a major concern worldwide, especially in the paediatric population. Vernal keratoconjunctivitis, a seasonal, chronic, bilateral inflammation of the ocular surface, represents one of the most common forms of ocular allergy in subtropical climates which may lead to corneal scarring and blindness if not properly treated. Late diagnosis of the disease and potential side effects of the currently used topical steroids, antihistamines, and mast cell stabilizers necessitates the development of early diagnostic tools and alternate immunosuppressive therapies. Mesenchymal stem cells have shown promising therapeutic potentials due to their tissue repair, anti-allergic, and immunomodulatory properties. However, their role in allergic conjunctivitis/vernal keratoconjunctivitis is poorly explored. Here, it is hypothesized that mesenchymal stem cells or their secreted products alleviate inflammation and promote repair of the damaged ocular surface in allergic conjunctivitis patients. It is presumed that they do so through multiple anti-allergic mechanisms and maintain long-term immunosuppression with significantly reduced or negligible side effects. These cells or their secreted products (extracellular vesicles, growth factors, conditioned medium, inflammatory mediators, and other biomolecules) can be used as topical immunosuppressive medications for effectively treating ocular surface inflammation in allergic conjunctivitis.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Eye</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Allergy</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Allergic conjunctivitis</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Immunomodulation</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Secretome</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Mesenchymal stem cells</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Das, Prabhudatta</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Jukanti, Avinash</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Mishra, Dilip Kumar</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Sahu, Srikant Kumar</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Basu, Sayan</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Shukla, Sachin</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Harcourt</subfield><subfield code="a">Fan, Ya-Meng ELSEVIER</subfield><subfield code="t">Hierarchical porous NiCo2S4-rGO composites for high-performance supercapacitors</subfield><subfield code="d">2017transfer abstract</subfield><subfield code="g">Burlington, Mass</subfield><subfield code="w">(DE-627)ELV015462293</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:162</subfield><subfield code="g">year:2022</subfield><subfield code="g">pages:0</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.mehy.2022.110813</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">44.00</subfield><subfield code="j">Medizin: Allgemeines</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">162</subfield><subfield code="j">2022</subfield><subfield code="h">0</subfield></datafield></record></collection>
|
| author |
Bhure, Tejal Sunil |
| spellingShingle |
Bhure, Tejal Sunil ddc 540 ddc 610 bkl 44.00 Elsevier Eye Elsevier Allergy Elsevier Allergic conjunctivitis Elsevier Immunomodulation Elsevier Secretome Elsevier Mesenchymal stem cells Mesenchymal stem cell therapy for alleviating ocular surface inflammation in allergic conjunctivitis |
| authorStr |
Bhure, Tejal Sunil |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)ELV015462293 |
| format |
electronic Article |
| dewey-ones |
540 - Chemistry & allied sciences 610 - Medicine & health |
| delete_txt_mv |
keep |
| author_role |
aut |
| collection |
elsevier |
| remote_str |
true |
| illustrated |
Not Illustrated |
| topic_title |
540 VZ 610 VZ 44.00 bkl Mesenchymal stem cell therapy for alleviating ocular surface inflammation in allergic conjunctivitis Eye Elsevier Allergy Elsevier Allergic conjunctivitis Elsevier Immunomodulation Elsevier Secretome Elsevier Mesenchymal stem cells Elsevier |
| topic |
ddc 540 ddc 610 bkl 44.00 Elsevier Eye Elsevier Allergy Elsevier Allergic conjunctivitis Elsevier Immunomodulation Elsevier Secretome Elsevier Mesenchymal stem cells |
| topic_unstemmed |
ddc 540 ddc 610 bkl 44.00 Elsevier Eye Elsevier Allergy Elsevier Allergic conjunctivitis Elsevier Immunomodulation Elsevier Secretome Elsevier Mesenchymal stem cells |
| topic_browse |
ddc 540 ddc 610 bkl 44.00 Elsevier Eye Elsevier Allergy Elsevier Allergic conjunctivitis Elsevier Immunomodulation Elsevier Secretome Elsevier Mesenchymal stem cells |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
zu |
| author2_variant |
p d pd a j aj d k m dk dkm s k s sk sks s b sb s s ss |
| hierarchy_parent_title |
Hierarchical porous NiCo2S4-rGO composites for high-performance supercapacitors |
| hierarchy_parent_id |
ELV015462293 |
| dewey-tens |
540 - Chemistry 610 - Medicine & health |
| hierarchy_top_title |
Hierarchical porous NiCo2S4-rGO composites for high-performance supercapacitors |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)ELV015462293 |
| title |
Mesenchymal stem cell therapy for alleviating ocular surface inflammation in allergic conjunctivitis |
| ctrlnum |
(DE-627)ELV057401594 (ELSEVIER)S0306-9877(22)00053-6 |
| title_full |
Mesenchymal stem cell therapy for alleviating ocular surface inflammation in allergic conjunctivitis |
| author_sort |
Bhure, Tejal Sunil |
| journal |
Hierarchical porous NiCo2S4-rGO composites for high-performance supercapacitors |
| journalStr |
Hierarchical porous NiCo2S4-rGO composites for high-performance supercapacitors |
| lang_code |
eng |
| isOA_bool |
false |
| dewey-hundreds |
500 - Science 600 - Technology |
| recordtype |
marc |
| publishDateSort |
2022 |
| contenttype_str_mv |
zzz |
| container_start_page |
0 |
| author_browse |
Bhure, Tejal Sunil |
| container_volume |
162 |
| class |
540 VZ 610 VZ 44.00 bkl |
| format_se |
Elektronische Aufsätze |
| author-letter |
Bhure, Tejal Sunil |
| doi_str_mv |
10.1016/j.mehy.2022.110813 |
| dewey-full |
540 610 |
| title_sort |
mesenchymal stem cell therapy for alleviating ocular surface inflammation in allergic conjunctivitis |
| title_auth |
Mesenchymal stem cell therapy for alleviating ocular surface inflammation in allergic conjunctivitis |
| abstract |
Allergic eye diseases have become a major concern worldwide, especially in the paediatric population. Vernal keratoconjunctivitis, a seasonal, chronic, bilateral inflammation of the ocular surface, represents one of the most common forms of ocular allergy in subtropical climates which may lead to corneal scarring and blindness if not properly treated. Late diagnosis of the disease and potential side effects of the currently used topical steroids, antihistamines, and mast cell stabilizers necessitates the development of early diagnostic tools and alternate immunosuppressive therapies. Mesenchymal stem cells have shown promising therapeutic potentials due to their tissue repair, anti-allergic, and immunomodulatory properties. However, their role in allergic conjunctivitis/vernal keratoconjunctivitis is poorly explored. Here, it is hypothesized that mesenchymal stem cells or their secreted products alleviate inflammation and promote repair of the damaged ocular surface in allergic conjunctivitis patients. It is presumed that they do so through multiple anti-allergic mechanisms and maintain long-term immunosuppression with significantly reduced or negligible side effects. These cells or their secreted products (extracellular vesicles, growth factors, conditioned medium, inflammatory mediators, and other biomolecules) can be used as topical immunosuppressive medications for effectively treating ocular surface inflammation in allergic conjunctivitis. |
| abstractGer |
Allergic eye diseases have become a major concern worldwide, especially in the paediatric population. Vernal keratoconjunctivitis, a seasonal, chronic, bilateral inflammation of the ocular surface, represents one of the most common forms of ocular allergy in subtropical climates which may lead to corneal scarring and blindness if not properly treated. Late diagnosis of the disease and potential side effects of the currently used topical steroids, antihistamines, and mast cell stabilizers necessitates the development of early diagnostic tools and alternate immunosuppressive therapies. Mesenchymal stem cells have shown promising therapeutic potentials due to their tissue repair, anti-allergic, and immunomodulatory properties. However, their role in allergic conjunctivitis/vernal keratoconjunctivitis is poorly explored. Here, it is hypothesized that mesenchymal stem cells or their secreted products alleviate inflammation and promote repair of the damaged ocular surface in allergic conjunctivitis patients. It is presumed that they do so through multiple anti-allergic mechanisms and maintain long-term immunosuppression with significantly reduced or negligible side effects. These cells or their secreted products (extracellular vesicles, growth factors, conditioned medium, inflammatory mediators, and other biomolecules) can be used as topical immunosuppressive medications for effectively treating ocular surface inflammation in allergic conjunctivitis. |
| abstract_unstemmed |
Allergic eye diseases have become a major concern worldwide, especially in the paediatric population. Vernal keratoconjunctivitis, a seasonal, chronic, bilateral inflammation of the ocular surface, represents one of the most common forms of ocular allergy in subtropical climates which may lead to corneal scarring and blindness if not properly treated. Late diagnosis of the disease and potential side effects of the currently used topical steroids, antihistamines, and mast cell stabilizers necessitates the development of early diagnostic tools and alternate immunosuppressive therapies. Mesenchymal stem cells have shown promising therapeutic potentials due to their tissue repair, anti-allergic, and immunomodulatory properties. However, their role in allergic conjunctivitis/vernal keratoconjunctivitis is poorly explored. Here, it is hypothesized that mesenchymal stem cells or their secreted products alleviate inflammation and promote repair of the damaged ocular surface in allergic conjunctivitis patients. It is presumed that they do so through multiple anti-allergic mechanisms and maintain long-term immunosuppression with significantly reduced or negligible side effects. These cells or their secreted products (extracellular vesicles, growth factors, conditioned medium, inflammatory mediators, and other biomolecules) can be used as topical immunosuppressive medications for effectively treating ocular surface inflammation in allergic conjunctivitis. |
| collection_details |
GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA |
| title_short |
Mesenchymal stem cell therapy for alleviating ocular surface inflammation in allergic conjunctivitis |
| url |
https://doi.org/10.1016/j.mehy.2022.110813 |
| remote_bool |
true |
| author2 |
Das, Prabhudatta Jukanti, Avinash Mishra, Dilip Kumar Sahu, Srikant Kumar Basu, Sayan Shukla, Sachin |
| author2Str |
Das, Prabhudatta Jukanti, Avinash Mishra, Dilip Kumar Sahu, Srikant Kumar Basu, Sayan Shukla, Sachin |
| ppnlink |
ELV015462293 |
| mediatype_str_mv |
z |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| author2_role |
oth oth oth oth oth oth |
| doi_str |
10.1016/j.mehy.2022.110813 |
| up_date |
2024-07-06T23:07:29.318Z |
| _version_ |
1803872894262968320 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV057401594</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230626045036.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">220808s2022 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.mehy.2022.110813</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">/cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001735.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV057401594</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S0306-9877(22)00053-6</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">540</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">44.00</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Bhure, Tejal Sunil</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Mesenchymal stem cell therapy for alleviating ocular surface inflammation in allergic conjunctivitis</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2022transfer abstract</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Allergic eye diseases have become a major concern worldwide, especially in the paediatric population. Vernal keratoconjunctivitis, a seasonal, chronic, bilateral inflammation of the ocular surface, represents one of the most common forms of ocular allergy in subtropical climates which may lead to corneal scarring and blindness if not properly treated. Late diagnosis of the disease and potential side effects of the currently used topical steroids, antihistamines, and mast cell stabilizers necessitates the development of early diagnostic tools and alternate immunosuppressive therapies. Mesenchymal stem cells have shown promising therapeutic potentials due to their tissue repair, anti-allergic, and immunomodulatory properties. However, their role in allergic conjunctivitis/vernal keratoconjunctivitis is poorly explored. Here, it is hypothesized that mesenchymal stem cells or their secreted products alleviate inflammation and promote repair of the damaged ocular surface in allergic conjunctivitis patients. It is presumed that they do so through multiple anti-allergic mechanisms and maintain long-term immunosuppression with significantly reduced or negligible side effects. These cells or their secreted products (extracellular vesicles, growth factors, conditioned medium, inflammatory mediators, and other biomolecules) can be used as topical immunosuppressive medications for effectively treating ocular surface inflammation in allergic conjunctivitis.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Allergic eye diseases have become a major concern worldwide, especially in the paediatric population. Vernal keratoconjunctivitis, a seasonal, chronic, bilateral inflammation of the ocular surface, represents one of the most common forms of ocular allergy in subtropical climates which may lead to corneal scarring and blindness if not properly treated. Late diagnosis of the disease and potential side effects of the currently used topical steroids, antihistamines, and mast cell stabilizers necessitates the development of early diagnostic tools and alternate immunosuppressive therapies. Mesenchymal stem cells have shown promising therapeutic potentials due to their tissue repair, anti-allergic, and immunomodulatory properties. However, their role in allergic conjunctivitis/vernal keratoconjunctivitis is poorly explored. Here, it is hypothesized that mesenchymal stem cells or their secreted products alleviate inflammation and promote repair of the damaged ocular surface in allergic conjunctivitis patients. It is presumed that they do so through multiple anti-allergic mechanisms and maintain long-term immunosuppression with significantly reduced or negligible side effects. These cells or their secreted products (extracellular vesicles, growth factors, conditioned medium, inflammatory mediators, and other biomolecules) can be used as topical immunosuppressive medications for effectively treating ocular surface inflammation in allergic conjunctivitis.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Eye</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Allergy</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Allergic conjunctivitis</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Immunomodulation</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Secretome</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Mesenchymal stem cells</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Das, Prabhudatta</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Jukanti, Avinash</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Mishra, Dilip Kumar</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Sahu, Srikant Kumar</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Basu, Sayan</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Shukla, Sachin</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Harcourt</subfield><subfield code="a">Fan, Ya-Meng ELSEVIER</subfield><subfield code="t">Hierarchical porous NiCo2S4-rGO composites for high-performance supercapacitors</subfield><subfield code="d">2017transfer abstract</subfield><subfield code="g">Burlington, Mass</subfield><subfield code="w">(DE-627)ELV015462293</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:162</subfield><subfield code="g">year:2022</subfield><subfield code="g">pages:0</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.mehy.2022.110813</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">44.00</subfield><subfield code="j">Medizin: Allgemeines</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">162</subfield><subfield code="j">2022</subfield><subfield code="h">0</subfield></datafield></record></collection>
|
| score |
7.399846 |